Brokerages Set Health Catalyst, Inc. (NASDAQ:HCAT) PT at $11.91

Shares of Health Catalyst, Inc. (NASDAQ:HCAT) have been given a consensus recommendation of “Moderate Buy” by the eleven analysts that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $11.91.

Several research analysts have commented on the company. Evercore ISI cut their target price on Health Catalyst from $9.00 to $8.00 and set an “outperform” rating for the company in a research note on Tuesday, July 9th. Wells Fargo & Company cut their target price on Health Catalyst from $14.00 to $13.00 and set an “overweight” rating for the company in a research note on Friday, May 10th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price target on shares of Health Catalyst in a report on Wednesday, April 10th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $11.00 price target on shares of Health Catalyst in a report on Tuesday, May 21st. Finally, Piper Sandler lowered their price target on Health Catalyst from $15.00 to $14.00 and set an “overweight” rating on the stock in a report on Thursday, June 6th.

Health Catalyst Stock Performance

HCAT stock opened at $7.69 on Tuesday. The company has a market capitalization of $453.98 million, a price-to-earnings ratio of -4.16 and a beta of 1.32. Health Catalyst has a fifty-two week low of $5.45 and a fifty-two week high of $14.37. The stock has a fifty day moving average of $6.62 and a 200-day moving average of $7.51.

Health Catalyst (NASDAQ:HCAT) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.05. The company had revenue of $74.72 million during the quarter, compared to the consensus estimate of $74.81 million. Health Catalyst had a negative return on equity of 11.86% and a negative net margin of 35.56%. Equities analysts predict that Health Catalyst will post -0.4 EPS for the current year.

Insider Activity at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 5,208 shares of Health Catalyst stock in a transaction that occurred on Wednesday, July 3rd. The stock was sold at an average price of $6.15, for a total value of $32,029.20. Following the transaction, the chief operating officer now directly owns 155,215 shares of the company’s stock, valued at approximately $954,572.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last three months, insiders have sold 8,564 shares of company stock valued at $54,889. Corporate insiders own 2.70% of the company’s stock.

Institutional Investors Weigh In On Health Catalyst

A number of large investors have recently made changes to their positions in the business. New York State Common Retirement Fund grew its position in shares of Health Catalyst by 1.3% in the 4th quarter. New York State Common Retirement Fund now owns 122,967 shares of the company’s stock worth $1,139,000 after buying an additional 1,582 shares during the last quarter. Principal Financial Group Inc. grew its stake in Health Catalyst by 6.9% in the second quarter. Principal Financial Group Inc. now owns 29,469 shares of the company’s stock worth $188,000 after purchasing an additional 1,907 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Health Catalyst by 23.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 15,072 shares of the company’s stock worth $140,000 after purchasing an additional 2,817 shares during the period. Price T Rowe Associates Inc. MD grew its stake in Health Catalyst by 6.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 49,746 shares of the company’s stock worth $375,000 after purchasing an additional 2,831 shares during the period. Finally, Nisa Investment Advisors LLC grew its stake in Health Catalyst by 461.0% in the second quarter. Nisa Investment Advisors LLC now owns 6,367 shares of the company’s stock worth $41,000 after purchasing an additional 5,232 shares during the period. 85.00% of the stock is currently owned by institutional investors.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.